Wayne, Pennsylvania, United States Devon Park BioVentures is the famous VC, which was founded in 2006. The company was established in North America in United States. The main department of described VC is located in the Wayne.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ZS Pharma, Diasome, MicuRx Pharmaceuticals. Among the most successful fund investment fields, there are Biotechnology, Nanotechnology. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
Besides them, we counted 2 critical employees of this fund in our database.
The top amount of exits for fund were in 2014. Considering the real fund results, this VC is 20 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2012. Opposing the other organizations, this Devon Park BioVentures works on 4 percentage points more the average amount of lead investments. The fund is generally included in less than 2 deals every year.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Devon Park BioVentures, startups are often financed by Intersouth Partners, TVM Capital, Prism Venture Management. The meaningful sponsors for the fund in investment in the same round are Intersouth Partners, TVM Capital, Skyline Ventures. In the next rounds fund is usually obtained by TVM Capital, Prism Venture Management, Intersouth Partners.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Asch | - |
| Bombora Group | - |
| Compass Genetics Investors | Delaware, Dover, United States |
| Corriente Advisors | Fort Worth, Texas, United States |
| EduLab | Japan, Tokyo |
| Hills Advertising | - |
| Huaige Capital | - |
| Huazhong Touzi | China, Shanghai |
| Iceni Seedcorn Fund | Norfolk, Norwich, United Kingdom |
| Meriken Nominees | - |
| NovX Capital | Latvia, Riga, Vidzeme |
| Palm Eco-Town Development Co.,Ltd. | China, Guangdong Province, Panyu District |
| Second City Capital | British Columbia, Canada, Vancouver |
| Target Accelerator | Bangalore, India, Karnataka |
| Tokyu Fudosan | Japan, Minato |
| Walter Ventures | Andalucia, Málaga, Spain |
| Weifang Chuangtou | China, Japan, Kagoshima Prefecture |
| Yuesheng Zichan | China, Guangdong Province, Yuexiu District |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cardeas Pharma | $37M | 10 Apr 2015 | Seattle, Washington, United States | ||
MicuRx Pharmaceuticals | $25M | 22 Aug 2013 | Hayward, California, United States | ||
ZS Pharma | $46M | 23 Oct 2012 | - | ||
Cardeas Pharma | $8M | 07 Jun 2012 | Seattle, Washington, United States | ||
Vascular Magnetics | $7M | 22 Feb 2012 | Philadelphia, Pennsylvania, United States | ||
Proteon Therapeutics | $15M | 12 Aug 2011 | Massachusetts, United States | ||
Cempra | $46M | 02 Jun 2009 | North Carolina, United States | ||
Proteon Therapeutics | $50M | 28 May 2009 | Massachusetts, United States | ||
Cara Therapeutics | $12M | 25 Jul 2008 | Connecticut, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cardeas Pharma | $37M | 10 Apr 2015 | Seattle, Washington, United States | ||
MicuRx Pharmaceuticals | $25M | 22 Aug 2013 | Hayward, California, United States | ||
ZS Pharma | $46M | 23 Oct 2012 | - | ||
Cardeas Pharma | $8M | 07 Jun 2012 | Seattle, Washington, United States | ||
Vascular Magnetics | $7M | 22 Feb 2012 | Philadelphia, Pennsylvania, United States | ||
Proteon Therapeutics | $15M | 12 Aug 2011 | Massachusetts, United States | ||
Cempra | $46M | 02 Jun 2009 | North Carolina, United States | ||
Proteon Therapeutics | $50M | 28 May 2009 | Massachusetts, United States | ||
Cara Therapeutics | $12M | 25 Jul 2008 | Connecticut, United States |
